Preclinical in vivo efficacy of two 9-dihydrotaxane analogues against human and murine tumours

British Journal of Cancer

Volumn 73, Issue 5, 1996, Pages 560-564

  Alder, J D ^a   Jarvis, K P ^a   Marsh, K C ^a   Klein, L L ^a   Clement, J J ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Analogues; Efficacy; Paclitaxel

Indexed keywords

10 DEACETYL 9 DIHYDROTAXOL; 9 DIHYDROTAXOL; ANTINEOPLASTIC AGENT; PACLITAXEL; PACLITAXEL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR; TUMOR XENOGRAFT;

EID: 0029911735     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.98     Document Type: Article

References (23)

1. BISSERY M-C, GUENARD D, GUERITTE-VOEGELEIN F AND LAVELLE F. (1991). Experimental antitumor activity of taxotere (RP 56976, NCS 628503), a paclitaxel analogue. Cancer Res., 51, 4845-4852.
2. CHABNER BA. (1991). Paclitaxel. In Principles and Practice of Oncology, Devitta VT, Hellman S and Rosenbert SA (eds) pp. 1 10. JB Lippincott: Philadelphia.
3. CHU D T W, HALLAS R, CLEMENT JJ, ALDER J, MCDONALD E AND PLATTNER JJ. (1992). Synthesis and antitumor activities of quinolones antiplastic agents. Drug Exp. Clin. Res., 18, 275-282.
4. EINZIG AL, TRUMP DL, SASLOFF J, GOROWSKI K, DUTCHER J AND WIERNIK PH (1988). Phase II pilot study of paclitaxel in patients with malignant melanoma. Proc. Am. Soc. Clin. Onco., 7, 249-253.
5. FUCHS D A AND JOHNSON RK. (1978). Cytologic evidence that paclitaxel, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat. Rep., 62, 1219-1222.
6. GERAN RI, GREENBERG RH, MACDONALD MM, SCHUMACHER AM AND ABBOTT BJ. (1972). Protocols for screening chemical agents and natural products against animal tumours and other biologic systems. Cancer Chemother. Rep., 3, 1-103.
7. GUNAWARDANA GP, PREMACHANDRAN U, BURRES NS, WHITTEN DN, HENRY R, SPATON S AND MCALPINE JB. (1992). Isolation of 9-dihydro-13-acetylbaccatin III from Taxus canadensis J. Natl. Prod., 55, 1686-1689.
8. HOLMES FA, ERYE D, THERIAULT RL, WALTERS RS, FOREMAN AD, NEWTON LK, BUZDAR AU AND HORTOBAGYI GN. (1991). Phase II study of paclitaxel in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 10, 60.
9. KLEIN LL. (1993). Synthesis of 9-dihydrotaxol: a novel bioactive taxane. Tetrahedron Lett., 34, 2047-2050.
10. KLEIN LL, MARING C, LI L, YEUNG CM, THOMAS SA, GRAMPOVNIK DJ, PLATTNER JJ AND HENRY RF. (1994). Synthesis of ring B-rearranged taxane analogues. J. Org. Chem., 59, 2370-2373.
11. LAVELLE F, FIZAMES C, GUERITTE-VOEGELEIN F, GUENARD D AND POTIER P (1989). Experimental properties of RP 56976, a paclitaxel derivative. Proc. Am. Assoc. Cancer Res., 30, 566.
12. LI L, THOMAS SA, KLEIN LL, YEUNG CM, MARING C, GRAMPOVNIK DJ, LARTEY P AND PLATTNER JJ. (1994). Synthesis and biologic evaluation of C3′ modified analogues of 9 (R) dihydrotaxol. J. Medic. Chem., 37, 2655-2663.
13. MCGUIRE WP, ROWINSKY EK, ROSENSHEIN NB, GRUMBINE FC, ETTINGER DS, ARMSTRONG DK AND DONEHOWER DC. (1989). Paclitaxel: a unique antineoplastic agent with significant activity in advanced ovarian epithelian neoplasms. Ann. Intern. Med., 111, 273-279.
14. NATIONAL CANCER INSTITUTE. (1985). Developmental Therapeutics Program Instruction, no. 14. Division of Cancer Treatment, Information Technology Branch, NCI: Bethesda, MD.
15. NATIONAL CANCER INSTITUTE. (1990). Paclitaxel (IND 22850, NSC 12973). Clinical brochure. Division of Cancer Treatment, NCI: Bethesda, MD.
16. RINGEL I AND HORWITZ SB (1991). Studies with RP 56976 (Taxotere): a semisynthetic analogue of paclitaxel. J. Natl Cancer Inst., 83, 288-291.
17. ROSE WC. (1981). Evaluation of Madison 109 lung carcinoma as a model for screening antitumor drugs. Cancer Treat., 65, 299-312.
18. ROSE WC. (1991). Paclitaxel: a review of its preclinical in vivo antitumor activity. Anti-Cancer Drugs, 3, 311-321.
19. ROWINSKY EK, BURKE PJ, KARP JE, TUCKER RW, ETTINGER DS AND DONEHOWER RC. (1989). Phase I and pharmacodynamic study of paclitaxel in refractory acute leukemias. Cancer Res., 49, 4640-4647.
20. SCHIFF PB, FANT J AND HORWITZ SB (1979). Promotion of microtubule assembly in vitro by paclitaxel. Nature, 22, 665-667.
21. SCHIFF SB. (1980). Paclitaxel stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA, 77, 1561-1565.
22. THIGPEN T, BLESSING J AND BALL H. (1990). Phase II trial of paclitaxel as a second line therapy for ovarian carcinomas: A gynecologic oncology group study. Proc. Am. Soc. Clin. Oncol., 9, 604.
23. WANI MC, TAYLOR HL, WALL ME, COGGON P AND MCPHAIL AT. (1971). Plant antitumor agents. VI. The isolation and structure of paclitaxel, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc., 93, 2325-2327.